Shares of Aratana Therapeutics Inc. (NASDAQ:PETX) were up 3% during trading on Monday . The stock traded as high as $9.37 and last traded at $9.34, with a volume of 655,721 shares trading hands. The stock had previously closed at $9.07.

Several analysts recently commented on PETX shares. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research note on Thursday, July 7th. Jefferies Group started coverage on Aratana Therapeutics in a research note on Friday, August 19th. They issued a “buy” rating and a $13.00 price target on the stock. Lake Street Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Aratana Therapeutics in a research note on Sunday, July 17th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $11.00 price target on shares of Aratana Therapeutics in a research note on Wednesday, August 10th. Finally, William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a research note on Wednesday, August 17th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $11.28.

The stock’s 50-day moving average is $8.00 and its 200 day moving average is $6.29. The stock’s market cap is $331.48 million.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.37. The business earned $38.05 million during the quarter, compared to analyst estimates of $15.14 million. During the same period in the prior year, the firm earned ($0.23) earnings per share. On average, equities research analysts forecast that Aratana Therapeutics Inc. will post ($0.73) EPS for the current fiscal year.

In related news, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total value of $462,500.00. Following the completion of the sale, the insider now directly owns 642,793 shares of the company’s stock, valued at approximately $5,945,835.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ernst Heinen sold 15,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $6.72, for a total value of $100,800.00. Following the completion of the sale, the insider now directly owns 125,494 shares of the company’s stock, valued at $843,319.68. The disclosure for this sale can be found here.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.